|Articles|June 1, 2021
Pharmasol Launches New psiXchange Capabilities
Advertisement
Pharmasol has announced the availability of psiXchange version 2.4, which automates the safety document distribution process within clinical trials. PsiXchange is an automated system that establishes relationships between data from multiple sources. The new enhancements within this release include expanded site views, enabling support of clinical operations and site-based teams, and provides information in real-time to a variety of global recipients involved in the drug safety management chain.
Safety documents like suspected unexpected serious adverse reactions (SUSARs), line listings and development safety update reports (DSURs) can be sent to all recipients including sites, ECs (ethics committees), IRBs (institutional review boards), and others through Safety Central (the smart portal that is part of psiXchange). These safety documents are automatically distributed using the embedded country rules and recipients’ language preferences.
For more information, click here.
Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Advertisement
Related Articles
- NIMBLE Trial Reveals New Insights on Complement Inhibition in gMG
September 15th 2025
- Q&A: Strategies for Successful Global Clinical Trial Delivery
September 12th 2025
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
Capvaxive Demonstrates Robust Immune Responses in Children, Adolescents at Increased Risk of Pneumococcal Disease
2
ACT Brief Weekly Recap: How AI, eClinical Innovation, and Policy Shifts Are Reshaping Clinical Research
3
NIMBLE Trial Reveals New Insights on Complement Inhibition in gMG
4
Phase IV Trial Shows Daybue Demonstrates Real-World Behavioral Improvements in Rett Syndrome
5